Enjoy complimentary customisation on priority with our Enterprise License!
The Binge-eating Disorder Treatment Market size is forecast to increase by USD 568.7 million, at a CAGR of 6.78% between 2023 and 2028. Market expansion relies on several factors, including the increasing prevalence of binge-eating disorders, the growing obese population, and the rising government initiatives addressing these health concerns. These dynamics collectively drive demand for products and services aimed at managing and treating binge-eating disorders and obesity. As the incidence of binge-eating disorders rises, there is a growing need for effective interventions and support services to address this mental health condition. Additionally, the global obesity epidemic has created a significant market for weight management products, dietary supplements, and healthcare services. Moreover, government initiatives aimed at promoting healthy lifestyles, combating obesity, and addressing mental health issues contribute to market growth by raising awareness and supporting prevention and treatment efforts. As these trends continue to evolve, they shape the landscape of the health and wellness industry, creating opportunities for innovation and intervention. It also includes an in-depth analysis of market trends and analysis, market growth analysis and challenges. Furthermore, the report includes historic market data from 2018 - 2022.
To learn more about this report, View Report Sample
The market addresses a pressing medical need for individuals battling psychological and non-psychological issues such as binge eating disorder and bulimia. With a focus on authentic and approved medications, this market caters to patients facing psychological problems like guilt and depression, alongside comorbid issues including diabetes and chronic pain. BED, classified as a medical disorder, involves excessive feeding leading to overweight or normal weight profiles, with symptoms characterized by a compulsion to binge eat and secretive consumption of food. As awareness grows, the Binge Eating Disorder Treatment Market offers hope through innovative medications and therapies, aiming to alleviate suffering and improve the quality of life for those affected. Our researchers analyzed the market research and growth data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
One of the key factors driving the market growth is the increasing prevalence of binge-eating disorder. As binge-eating disorders is prevalent across all age groups, races, and income levels, it can significantly contribute to the Market growth. For instance, in the US, this condition has a lifetime frequency of 2.6%. 49% of people with binge-eating disorders have a lifetime history of two or more comorbid disorders; around 79% of people with binge-eating disorders have one psychiatric disorder.
As the patients have to face a lot of impairments in their lifestyle that are treated by the medications available in the market, It is fuelling the revenue growth of the market. Furthermore, the symptomatic treatment by antidepressants is helping in preventing various patients from complications of binge-eating disorder. Hence, such factors can significantly drive the global Market during the forecast period.
A key factor shaping the market growth is the development and approval of new drugs. Pharmaceutical vendors are significantly developing new binge-eating disorder treatments for approval as there is an increasing prevalence of binge-eating disorders. For instance, in 2022, Tonix Pharmaceuticals Holding Corp. and Massachusetts General Hospital announced an agreement to assess TNX-1900 as a probable treatment for patients with binge-eating disorders.
Furthermore, in January 2023, Tryp Therapeutics announced interim results of its Phase II trial with psilocybin (TRP-8803) for the treatment of binge-eating disorder, with daily binge-eating episodes reduced by an average of 80%. Thus the development and approval of new drugs continues to drive the global Market during the forecast period.
Side effects of binge-eating disorder drugs are the key challenges hindering the market growth. Factors such as the use of binge-eating disorder drugs during pregnancy may lead to congenital abnormalities and stillbirths, and binge-eating disorder drugs cause spontaneous abortion, persistent pulmonary hypertension in newborns, low birth weight, gestational hypertension, prematurity, postpartum hemorrhage, and delayed motor development in the newborn can significantly decrease the adoption of binge-eating disorder treatment.
Furthermore, binge-eating disorder drugs produce physical side effects such as headaches, insomnia/hypersomnia, and gastric distress, as well as emotional side effects including hyperactivity, hostility, emotional lability, irritability, and self-harm. Thus, these side effects can impede the global Market during the forecast period.
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth and forecasting strategies.
Market Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Alvogen Iceland ehf - The company offers a binge-eating disorder treatment drug called Forfivo XL tablets under its subsidiary called Almatica.
The research report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The market share growth by the offline segment will be significant during the forecast period. The offline sector dominated the global binge-eating disorder treatment market and held the largest share in 2022. As offline stores offer product assurance, authenticity, and verification, most customers prefer buying through offline distribution channels.
Get a glance at the market contribution of various segments View the PDF Sample
The offline segment was valued at USD 809.60 million in 2018. The offline store has several advantages based on factors such as geographical presence, ease of production and inventory management, and goods transportation. Market players significantly invest in brick-and-mortar organized retail stores to increase their regional and global shares in the market. Due to the increased footfall in offline stores, vendors are investing in brick-and-mortar stores to sell binge-eating disorder treatment drugs. Thus, it is anticipated that a rise in the retail sector, which improves access to items, will accelerate offline segment growth, which, in turn, will boost the growth of the global binge-eating disorder treatment market during the forecast period.
For more insights on the market share of various regions Download PDF Sample now!
North America is estimated to contribute 35% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. The growth of the regional market can be attributed to factors such as the high prevalence of binge-eating disorders and the availability of several treatments. There is an increasing prevalence of binge-eating disorders in the US, which offers opportunities for growth in the market in North America.
Also, according to The World Bank Group (WBG), in 2020, healthcare expenditure in the US increased by 9.7% and reached USD 4.1 trillion or USD 12,530 per person. Furthermore, the country's healthcare expenditure accounted for 19.7% of its gross domestic product (GDP) in 2020. Hence, such factors drive regional market growth during the forecast period.
The market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in "USD million" for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.
You may also interested in below market reports:
The market tackles a spectrum of challenges, from non-psychological problems to comorbid issues such as anxiety disorders, mood disorders, and substance use disorders. With psychotherapy and medication playing crucial roles, doctors focus on accurate disorder diagnosis and individualized treatment therapy. However, the costly treatment landscape demands innovative solutions. Antidepressant drugs like Lisdexamfetamine with Methylphenidate and serotonergic antidepressants show promise, alongside emerging options like Centanafadine Sustained-release Tablets and Solriamfetol. As the market expands, healthcare facilities evolve to accommodate large pools of patients, while ongoing clinical trials and research in prestigious journals like Biological Psychiatry and Psychiatry Research drive advancements in the pharmaceuticals category, aiming to alleviate suffering and improve outcomes for individuals with severe binge eating disorders.
Further, in the realm of binge-eating disorder (BED) treatment, addressing comorbid problems and general medical illnesses is paramount. This includes tackling impulse-control disorders and conditions like anorexia, gastrointestinal problems, and insomnia, often aggravated by sympathetic nervous system activation. Treatment approaches emphasize individualization to cater to diverse needs, leveraging a spectrum of treatment options. As healthcare expenditures rise, there's a parallel expansion of healthcare facilities, facilitating access for the large pool of patients affected by mild to severe binge eating disorders. Clinical trials, including Phase 2 and Phase 4 studies, drive innovation, with drugs like Dasotraline awaiting New Drug Application (NDA) approval. Despite challenges like medical complications and cardiac diseases, advancements in treatment hold promise for improving outcomes and enhancing the quality of life for those affected.
Industry Scope |
|
Report Coverage |
Details |
Page number |
164 |
Base year |
2023 |
Historic period |
2018-2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 6.78% |
Market Growth 2024-2028 |
USD 568.7 million |
Market structure |
Concentrated |
YoY growth 2023-2024(%) |
6.24 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 35% |
Key countries |
US, UK, Germany, China, and India |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
Alvogen Iceland ehf, Bausch Health Companies Inc., Chronos Therapeutics Ltd., Currax Pharmaceuticals LLC, Eli Lilly and Co., Johnson and Johnson Services Inc., Lupin Ltd., Omeros Corp., Pyramid Healthcare Inc., Rosewood Centers for Eating disorders, Sumitomo Pharma Co. Ltd., Takeda Pharmaceutical Co. Ltd., Timberline Knolls Residential Treatment Center, Tonix Pharmaceuticals Holding Corp., Tryp Therapeutics Inc., Viatris Inc., VIVUS LLC, and Walden Behavioral Care |
Market dynamics |
Parent market analysis, Market forecast, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period. |
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements.
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Distribution Channel
7 Market Segmentation by Type
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.